Dezanet LNC, Miailhes P, Lascoux-Combe C, et al. - Researchers aimed at describing the profiles of liver fibrosis evolution in individuals with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection during treatment with tenofovir (TDF). Among 169 HIV-HBV-coinfected patients on TDF-based antiretroviral therapy, they identified four profiles of liver fibrosis evolution from a median follow-up of 7.6 years: low fibrosis with no progression (29.6%, Profile A), low fibrosis with progression (22.5%, Profile B), moderate fibrosis with high fluctuation (39.6%, Profile C), and cirrhosis with no regression (8.3%, Profile D). Findings suggest that benefits obtained from TDF-treatment in HIV-HBV coinfected individuals were not of comparable levels in terms of liver fibrosis regression as observed in cases with HBV mono-infection. Those with fluctuating or consistently high fibrosis levels mainly exhibited liver-related morbidity.